Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    CCSB Semaglutide

    Virtual Booth

    Contact Supplier

    Semaglutide

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Semaglutide

    Virtual Booth

    Contact Supplier

    Semaglutide

    Virtual Booth

    Contact Supplier

    Menu

    Semaglutide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 484,828Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 5Novo Nordisk Canada Inc.

    filter clear-filterReset all filters

    filter clear-filterReset all filters

    filter clear-filterReset all filters

    filter clear-filterReset all filters

    PharmaCompass
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Novo Nordisk Canada Inc.

    SEMAGLUTIDE
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Novo Nordisk Canada Inc.

    Country
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Patent Expiration Date : 2026-03-20

    Date Granted : 2013-12-24

    SEMAGLUTIDE

    Brand Name : OZEMPIC

    Patent Number : 2601784

    Filing Date : 2006-03-20

    Strength per Unit : 1.34 mg / mL

    Dosage Form : SOLUTION

    Human Or VET : Human

    Route of Administration : SUBCUTANEOUS

    Patent Expiration Date : 2026-03-20

    Date Granted : 2013-12-24

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Novo Nordisk Canada Inc.

    SEMAGLUTIDE
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Novo Nordisk Canada Inc.

    Country
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Patent Expiration Date : 2026-03-20

    Date Granted : 2013-12-24

    SEMAGLUTIDE

    Brand Name : OZEMPIC

    Patent Number : 2601784

    Filing Date : 2006-03-20

    Strength per Unit : 1.34 mg / mL

    Dosage Form : SOLUTION

    Human Or VET : Human

    Route of Administration : SUBCUTANEOUS

    Patent Expiration Date : 2026-03-20

    Date Granted : 2013-12-24

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Novo Nordisk Canada Inc.

    SEMAGLUTIDE
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Novo Nordisk Canada Inc.

    Country
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Patent Expiration Date : 2026-03-20

    Date Granted : 2013-12-24

    SEMAGLUTIDE

    Brand Name : RYBELSUS

    Patent Number : 2601784

    Filing Date : 2006-03-20

    Strength per Unit : 3 mg

    Dosage Form : TABLET

    Human Or VET : Human

    Route of Administration : ORAL

    Patent Expiration Date : 2026-03-20

    Date Granted : 2013-12-24

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Novo Nordisk Canada Inc.

    SEMAGLUTIDE
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Novo Nordisk Canada Inc.

    Country
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Patent Expiration Date : 2026-03-20

    Date Granted : 2013-12-24

    SEMAGLUTIDE

    Brand Name : RYBELSUS

    Patent Number : 2601784

    Filing Date : 2006-03-20

    Strength per Unit : 7 mg

    Dosage Form : TABLET

    Human Or VET :

    Route of Administration : ORAL

    Patent Expiration Date : 2026-03-20

    Date Granted : 2013-12-24

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Novo Nordisk Canada Inc.

    SEMAGLUTIDE
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Novo Nordisk Canada Inc.

    Country
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Patent Expiration Date : 2026-03-20

    Date Granted : 2013-12-24

    SEMAGLUTIDE

    Brand Name : RYBELSUS

    Patent Number : 2601784

    Filing Date : 2006-03-20

    Strength per Unit : 14 mg

    Dosage Form : TABLET

    Human Or VET : Human

    Route of Administration : ORAL

    Patent Expiration Date : 2026-03-20

    Date Granted : 2013-12-24

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.